Skip to main content
Premium Trial:

Request an Annual Quote

Menarini to Distribute QuantuMDx Point-of-Care MDx System, Tests in UK and France

NEW YORK — QuantuMDx has signed a distribution agreement for its Q-POC point-of-care molecular diagnostics system and certain related tests in the UK and France with A. Menarini Diagnostics, the companies said on Wednesday.

Under the terms of the five-year deal, Menarini Diagnostics — a part of Italy's Menarini Pharmaceutical Group — will market, sell, and service Q-POC, along with QuantuMDx's SARS-CoV-2 assay and combination SARS-CoV-2, influenza A/B, and respiratory syncytial virus panel.

The arrangement will initially cover France and the UK, but could potentially be expanded to other markets.

Financial and other terms were not disclosed.

"The agreement will allow us to further accelerate commercial sales of Q-POC, bringing our point-of-need multiplex molecular diagnostics platform to clinical and nonclinical settings in a host of new markets," QuantuMDx CEO Jonathan O'Halloran said in a statement.

In September, Newcastle, UK-based QuantuMDx partnered with Sansure Biotech to commercialize the Q-POC system and assays in China.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.